Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/123757
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Targeting PCNA with peptide mimetics for therapeutic purposes
Author: Horsfall, A.J.
Abell, A.D.
Bruning, J.
Citation: ChemBioChem: a European journal of chemical biology, 2020; 21(4):442-450
Publisher: Wiley
Issue Date: 2020
ISSN: 1439-7633
1439-7633
Statement of
Responsibility: 
Aimee J. Horsfall, Andrew D. Abell and John B. Bruning
Abstract: Proliferating cell nuclear antigen (PCNA) is an excellent inhibition target to shut down highly proliferative cells and thereby develop a broad‐spectrum cancer therapeutic. It interacts with a wide variety of proteins through a conserved motif referred to as the PCNA‐interacting protein (PIP) box. There is large sequence diversity between high‐affinity PCNA binding partners, but with conservation of the binding structure - a well‐defined 3₁₀‐helix. Herein, all current PIP‐box peptides crystallised with human PCNA are collated to reveal common trends between binding structure and affinity. Key intra‐ and intermolecular hydrogen‐bonding networks that stabilise the 3₁₀‐helix of PIP‐box partners are highlighted and related back to the canonical PIP‐box motif. High correlation with the canonical PIP‐box sequence does not directly afford high affinity. Instead, we summarise key interactions that stabilise the binding structure that leads to enhanced PCNA binding affinity. These interactions also implicate the “non‐conserved” residues within the PIP‐box that have previously been overlooked. Such insights will allow a more directed approach to develop therapeutic PCNA inhibitors.
Keywords: PCNA; peptide mimetics
Rights: © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
DOI: 10.1002/cbic.201900275
Grant ID: http://purl.org/au-research/grants/arc/CE140100003
Appears in Collections:Aurora harvest 4
Chemistry publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.